Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347)
:3347
Want to see HK:3347 full AI Analyst Report?
Top Page
Hangzhou Tigermed Consulting Co., Ltd. Class H
(3347)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$35.00
▼(-35.19% Downside)
Action:Reiterated
Date:04/30/26
The score is supported primarily by solid financial performance (low leverage, stabilized margins, and positive free cash flow). It is held back by weak technicals (below key moving averages with negative MACD) and a relatively expensive valuation (high P/E with a modest dividend yield).
Positive Factors
Conservative balance sheet
Low reported leverage (≈7% debt-to-equity TTM) provides durable financial flexibility. For a CRO with lumpy receivables and long study timelines, conservative gearing reduces refinancing risk, supports bidding for larger multi-country studies, and preserves capacity to invest or weather trial payment cycles.
Negative Factors
Low returns on equity
A modest ROE (~4% TTM) indicates limited efficiency in converting capital into profits versus historical peaks. Over the medium term, low ROE constrains the company’s ability to self-fund growth, reduces shareholder return potential, and highlights the need to improve pricing, utilization, or operational leverage to restore capital efficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low reported leverage (≈7% debt-to-equity TTM) provides durable financial flexibility. For a CRO with lumpy receivables and long study timelines, conservative gearing reduces refinancing risk, supports bidding for larger multi-country studies, and preserves capacity to invest or weather trial payment cycles.
Read all positive factors
Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$38.69B
Dividend Yield0.8%
Average Volume (3M)2.64M
Price to Earnings (P/E)151.9
Beta (1Y)1.84
Revenue Growth10.65%
EPS Growth134.38%
CountryHK
Employees10,185
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.90
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$55.20Price Target Upside2.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.29
Revenue Forecast (FY)HK$8.79B
Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The comp...
How the Company Makes Money
Tigermed primarily makes money by charging customers (pharma/biotech and medical device sponsors) service fees under CRO contracts to run and support clinical development programs. Key revenue streams typically include: (1) Clinical trial services...
Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
86
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.07B | 6.83B | 6.60B | 7.38B | 7.09B | 5.21B |
| Gross Profit | 1.88B | 1.87B | 2.24B | 2.85B | 2.81B | 2.27B |
| EBITDA | 1.83B | 1.42B | 1.13B | 2.91B | 2.93B | 3.90B |
| Net Income | 903.80M | 887.89M | 405.14M | 2.02B | 2.01B | 2.87B |
Balance Sheet | ||||||
| Total Assets | 28.80B | 28.36B | 28.67B | 29.68B | 27.45B | 23.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.20B | 1.84B | 2.13B | 7.46B | 7.88B | 8.57B |
| Total Debt | 1.53B | 1.47B | 2.63B | 2.83B | 2.80B | 1.19B |
| Total Liabilities | 4.24B | 4.10B | 4.61B | 5.23B | 4.77B | 3.14B |
| Stockholders Equity | 20.92B | 20.96B | 20.67B | 21.03B | 19.58B | 18.12B |
Cash Flow | ||||||
| Free Cash Flow | 1.17B | 903.72M | 740.45M | 836.68M | 908.90M | 1.06B |
| Operating Cash Flow | 1.39B | 1.12B | 1.10B | 1.15B | 1.36B | 1.42B |
| Investing Cash Flow | 1.01B | 491.56M | -4.74B | -1.53B | -2.79B | -2.78B |
| Financing Cash Flow | -1.78B | -1.93B | -1.70B | -7.81M | 809.25M | -163.09M |
Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis
Negative
54.00
Price Trends
40.84
Negative
44.71
Negative
45.52
Negative
Market Momentum
-2.00
Positive
27.91
Positive
15.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Negative. The current price of 54 is above the 20-day moving average (MA) of 39.22, above the 50-day MA of 40.84, and above the 200-day MA of 45.52, indicating a bearish trend. The MACD of -2.00 indicates Positive momentum. The RSI at 27.91 is Positive, neither overbought nor oversold. The STOCH value of 15.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3347.
Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$29.35B | 16.51 | 19.93% | 1.84% | -0.47% | -11.25% | |
70 Outperform | HK$47.97B | 23.82 | 6.34% | 1.57% | 18.78% | 12.65% | |
68 Neutral | HK$51.05B | 22.45 | 11.22% | 1.04% | 16.83% | -8.65% | |
67 Neutral | HK$22.57B | 40.43 | 21.21% | 0.63% | 6.10% | 16.45% | |
62 Neutral | HK$38.69B | 151.86 | 3.69% | 0.80% | 10.65% | 134.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
33.06
6.03
22.30%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
18.28
4.86
36.19%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
44.76
19.08
74.30%
HK:2367
Giant Biogene Holding Co. Ltd.
28.00
-51.91
-64.96%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
92.40
27.42
42.20%
Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events
Tigermed Calls June EGM to Seek Approval for A-Share Buyback Mandate
May 19, 2026
Hangzhou Tigermed Consulting Co., Ltd. has called a second extraordinary general meeting for June 9, 2026, in Hangzhou to seek shareholder approval for a special resolution authorizing the repurchase of its A shares via centralized price bidding. ...
Tigermed Calls 2026 H Shareholders’ Meeting to Approve A Share Buyback Mandate
May 19, 2026
Hangzhou Tigermed Consulting Co., Ltd. has convened a 2026 second H share class meeting in Hong Kong for holders of its H shares, to be held on June 9, 2026 after its extraordinary general and A share class meetings. The session will be conducted ...
Hangzhou Tigermed Unveils Up to RMB1 Billion A-Share Buyback Plan
May 13, 2026
Hangzhou Tigermed Consulting has unveiled a plan to repurchase between RMB500 million and RMB1 billion of its publicly held A shares through centralized price bidding, at a maximum price of RMB60 per share. The repurchased stock will be partly all...
Tigermed Says Probe Into Major Shareholders Will Not Hit Operations
May 13, 2026
Hangzhou Tigermed Consulting has issued a clarification following market speculation about whether its controlling shareholders, chairman Ye Xiaoping and director Cao Xiaochun, complied with disclosure rules on past shareholding changes. The compa...
Tigermed Directors Probed by CSRC Over Shareholding Disclosures
May 12, 2026
Hangzhou Tigermed Consulting has disclosed that two of its directors and controlling shareholders, chairman Ye Xiaoping and director Cao Xiaochun, are under investigation by the China Securities Regulatory Commission for suspected violations relat...
Hangzhou Tigermed Updates 2025 Final Dividend Terms and Tax Treatment
Apr 29, 2026
Hangzhou Tigermed Consulting has announced an updated final cash dividend for the year ended 31 December 2025, declaring a payout of RMB 1.26 per 10 shares, subject to shareholder approval on 2 June 2026. The dividend for Hong Kong shareholders wi...
Tigermed Sets 2025 AGM to Decide Dividends, Board Mandates and Governance Changes
Apr 29, 2026
Hangzhou Tigermed Consulting Co., Ltd. has called its 2025 annual general meeting for June 2, 2026 in Hangzhou, where shareholders will review the 2025 operating year, including the annual report, board report, final financial report and profit di...
Tigermed Sets 2026 H Share Class Meeting to Seek H-Share Buyback Mandate
Apr 29, 2026
Hangzhou Tigermed Consulting has called its 2026 First H Share Class Meeting for June 2, 2026 in Hangzhou, following its 2025 annual general meeting and the 2026 first A share class meeting. H shareholders on the register as of that date may atten...
Hangzhou Tigermed issues unaudited 2026 first-quarter report
Apr 28, 2026
Hangzhou Tigermed Consulting has released its unaudited first quarterly report for the 2026 financial year, prepared under China Accounting Standards for Business Enterprises. The document, published in both Chinese and English with the Chinese ve...
Tigermed Sets April 28 Board Meeting to Approve First-Quarter 2026 Results
Apr 16, 2026
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for April 28, 2026 to review and approve its first quarterly report for the period ended March 31, 2026. The meeting may also cover additional board resolutions, signaling routin...
Tigermed Plans Governance Revamp With New Vice Chairman and Expanded Co-President Roles
Mar 30, 2026
Hangzhou Tigermed Consulting Co., Ltd. has proposed amendments to its articles of association to add the role of vice chairman to its seven-member board and to increase the number of co-presidents from one to two, reflecting evolving operational a...
Hangzhou Tigermed Proposes 2025 Final Dividend With Key Details Pending
Mar 30, 2026
Hangzhou Tigermed Consulting has proposed a final ordinary cash dividend of RMB 1.26 per 10 shares for the financial year ended 31 December 2025, with payment scheduled for 31 July 2026. Key details including shareholder approval date, currency fo...
Tigermed Proposes New Three-Year Board Line-Up to Maintain Strategic Continuity
Mar 30, 2026
Hangzhou Tigermed Consulting Co., Ltd. has outlined the composition of its sixth board, proposing seven directors in line with Chinese company law and its articles of association, including one employee director. The company seeks shareholder appr...
Tigermed Lifts Headline Profit and Dividend Despite Margin Squeeze in 2025
Mar 30, 2026
Hangzhou Tigermed Consulting reported modest revenue growth for 2025, with sales rising 3.5% year-on-year to RMB 6.83 billion, while gross profit declined 16.4% and gross margin fell to 27.4%, highlighting pressure on operating efficiency. Despite...
Tigermed Sets March 30 Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 18, 2026
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for March 30, 2026, to review and approve the annual results for the year ended December 31, 2025, for the company and its subsidiaries, and to authorize their release. The board...
Tigermed Shareholders Approve Special Resolution at 2026 Extraordinary Meeting
Mar 5, 2026
Hangzhou Tigermed Consulting Co., Ltd. reported that its first extraordinary general meeting of 2026 was duly convened in Hangzhou on March 5, with all seven directors in attendance either in person or via video. The meeting, chaired by board chai...
Tigermed Completes Intra-Group Disposal With No Material Financial Impact
Mar 3, 2026
Hangzhou Tigermed Consulting has completed the intra-group disposal of a target group of subsidiaries under a share transfer agreement, with all conditions precedent fulfilled and completion taking place on March 3, 2026. The target company and it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.